Literature DB >> 29251543

The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension.

David F Meoli1, Yan Ru Su1, Evan L Brittain1, Ivan M Robbins2, Anna R Hemnes2, Ken Monahan1.   

Abstract

Pulmonary hypertension complicating left heart disease (PH-LHD) is associated with increased morbidity and mortality, especially in patients who develop combined pre- and post-capillary PH (Cpc-PH). Mechanisms underlying PH-LHD are incompletely understood, particularly for individuals with preserved left ventricular ejection fraction (LVEF). We hypothesized that transpulmonary concentrations of biomarkers representing signaling pathways with known effects on the pulmonary circulation could provide insight into the molecular etiology of PH-LHD in patients with preserved LVEF. Blood samples were collected from the pulmonary artery (PA) and wedge positions of outpatients with normal LVEF referred for right heart catheterization. Hemodynamic tracings were reviewed to classify patients as "no PH" (n = 23) or "PH-LHD" (n = 22). A biomarker's transpulmonary ratio (TPR) was calculated as the quotient of wedge and PA concentrations. The TPR of endothelin 1 (ET-1) was elevated in Cpc-PH (n = 10) compared to no PH or isolated post-capillary PH (Ipc-PH, n = 12); cAMP and cGMP TPRs were not different among groups. Higher ET-1 TPR in Cpc-PH was due to increased wedge ET-1 concentration. Pulmonary vascular resistance (PVR) strongly correlated with wedge ET-1 exclusively in Cpc-PH patients. In patients with normal LVEF and Cpc-PH, ET-1 TPR is higher, due to elevated wedge ET-1, compared to those without PH or with Ipc-PH. Strong correlation between PVR and wedge ET-1, observed only in the Cpc-PH group, may suggest increased pulmonary vascular responsiveness to ET-1 in these patients. These findings implicate elevated pulmonary ET-1 as a marker of, and a potential contributor to, development of Cpc-PH in this population.

Entities:  

Keywords:  biomarker; cardiopulmonary physiology and pathophysiology; endothelin; heart failure; hemodynamics

Year:  2017        PMID: 29251543      PMCID: PMC5764145          DOI: 10.1177/2045893217745019

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  33 in total

1.  Prognostic value of plasma endothelin-1 in patients with chronic heart failure.

Authors:  F Pousset; R Isnard; P Lechat; H Kalotka; A Carayon; G Maistre; S Escolano; D Thomas; M Komajda
Journal:  Eur Heart J       Date:  1997-02       Impact factor: 29.983

2.  Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study.

Authors:  Ronald Van Beneden; Olivier Gurné; Philippe L Selvais; Sylvie A Ahn; Annie R Robert; Jean-Marie Ketelslegers; Hubert G Pouleur; Michel F Rousseau
Journal:  J Card Fail       Date:  2004-12       Impact factor: 5.712

3.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

4.  Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension.

Authors:  Christian Gerges; Mario Gerges; Marie B Lang; Yuhui Zhang; Johannes Jakowitsch; Peter Probst; Gerald Maurer; Irene M Lang
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

5.  Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure.

Authors:  M Hülsmann; B Stanek; B Frey; B Sturm; D Putz; T Kos; R Berger; W Woloszczuk; D Putz; T Kos; R Berger; W Woloszczuk; G Maurer; R Pacher
Journal:  J Am Coll Cardiol       Date:  1998-11-15       Impact factor: 24.094

6.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.

Authors:  Inder Anand; John McMurray; Jay N Cohn; Marvin A Konstam; Thomas Notter; Kurt Quitzau; Frank Ruschitzka; Thomas F Lüscher
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

7.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

8.  Plasma endothelin in chronic heart failure.

Authors:  J J McMurray; S G Ray; I Abdullah; H J Dargie; J J Morton
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690

9.  Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

Authors:  D J Stewart; R D Levy; P Cernacek; D Langleben
Journal:  Ann Intern Med       Date:  1991-03-15       Impact factor: 25.391

10.  Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.

Authors:  Diana Bonderman; Ingrid Pretsch; Regina Steringer-Mascherbauer; Pavel Jansa; Stephan Rosenkranz; Caroline Tufaro; Andja Bojic; Carolyn S P Lam; Reiner Frey; Michael Ochan Kilama; Sigrun Unger; Lothar Roessig; Irene M Lang
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

View more
  12 in total

Review 1.  Pulmonary Hypertension Due to Left Heart Disease: an Update.

Authors:  Mandar A Aras; Mitchell A Psotka; Teresa De Marco
Journal:  Curr Cardiol Rep       Date:  2019-05-27       Impact factor: 2.931

2.  Endothelin-1, cardiac morphology, and heart failure: the MESA angiogenesis study.

Authors:  Peter J Leary; Nancy S Jenny; David A Bluemke; Steven M Kawut; Richard A Kronmal; Joao A Lima; Bradley A Maron; David D Ralph; Samuel G Rayner; John J Ryan; Zachary L Steinberg; Karen D Hinckley Stukovsky; Ryan J Tedford
Journal:  J Heart Lung Transplant       Date:  2019-08-10       Impact factor: 10.247

Review 3.  Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction.

Authors:  Andrea R Levine; Marc A Simon; Mark T Gladwin
Journal:  Trends Cardiovasc Med       Date:  2018-08-17       Impact factor: 6.677

4.  Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: a key role for endothelin.

Authors:  Richard W B van Duin; Kelly Stam; Zongye Cai; André Uitterdijk; Ana Garcia-Alvarez; Borja Ibanez; A H Jan Danser; Irwin K M Reiss; Dirk J Duncker; Daphne Merkus
Journal:  J Physiol       Date:  2018-06-21       Impact factor: 5.182

5.  CD44 and xCT: The Silver Bullet for Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension?

Authors:  Vineet Agrawal; Anna R Hemnes
Journal:  Am J Respir Cell Mol Biol       Date:  2019-09       Impact factor: 6.914

Review 6.  The Biological Bases of Group 2 Pulmonary Hypertension.

Authors:  Ana I Fernández; Raquel Yotti; Ana González-Mansilla; Teresa Mombiela; Enrique Gutiérrez-Ibanes; Candelas Pérez Del Villar; Paula Navas-Tejedor; Christian Chazo; Pablo Martínez-Legazpi; Francisco Fernández-Avilés; Javier Bermejo
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

7.  Trans-right ventricle and transpulmonary metabolite gradients in human pulmonary arterial hypertension.

Authors:  Philippe Chouvarine; Martin Giera; Gabi Kastenmüller; Anna Artati; Jerzy Adamski; Harald Bertram; Georg Hansmann
Journal:  Heart       Date:  2020-02-20       Impact factor: 5.994

Review 8.  Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?

Authors:  Kondababu Kurakula; Valérie F E D Smolders; Olga Tura-Ceide; J Wouter Jukema; Paul H A Quax; Marie-José Goumans
Journal:  Biomedicines       Date:  2021-01-09

9.  Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension.

Authors:  Vineet Agrawal; Niki Fortune; Sheeline Yu; Julio Fuentes; Fubiao Shi; David Nichols; Linda Gleaves; Emily Poovey; Thomas J Wang; Evan L Brittain; Sheila Collins; James D West; Anna R Hemnes
Journal:  Pulm Circ       Date:  2019-12-18       Impact factor: 3.017

10.  Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension.

Authors:  Wei-Ting Chang; Jhih-Yuan Shih; Chon-Seng Hong; Yu-Wen Lin; Yi-Chen Chen; Chung-Han Ho; Zhih-Cherng Chen; Jun-Neng Roan; Chih-Hsin Hsu
Journal:  ESC Heart Fail       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.